[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342670-105":59,"doc-detail-342670-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","site-specific-glycosylation-analysis-of-epidermal-growth-factor-receptor-2-erbb2-exploring-structure-and-function-toward-therapeutic-targeting","Site-specific glycosylation analysis of epidermal growth factor receptor 2 (ErbB2) - exploring structure and function toward therapeutic targeting","","Site-specific glycosylation analysis of epidermal growth factor receptor 2 (ErbB2) investigates how defined glycan structures contribute to receptor structure, stability, and signaling relevant to cancer therapy. Mass spectrometry establishes a “glycoform atlas” covering both N-linked and serine/threonine-linked glycosylation sites. Molecular dynamics simulations of N-glycosylated ErbB2 identify the N124 glycan on a flexible loop as important for structural stabilization, while an N124 glycosylation-deficient mutant shows reduced intracellular half-life and suppressed autophosphorylation. Comparative analysis with EGFR reveals distinct N-glycan distribution and density patterns that support glycan-targeted therapeutic design.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/site-specific-glycosylation-analysis-of-epidermal-growth-factor-receptor-2-erbb2-exploring-structure-and-function-toward-therapeutic-targeting/342670/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/site-specific-glycosylation-analysis-of-epidermal-growth-factor-receptor-2-erbb2-exploring-structure-and-function-toward-therapeutic-targeting/342670.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of this ErbB2 glycosylation study?","Question",{"text":112,"@type":113},"To define the site-specific glycan structures on ErbB2 and clarify how those glycans influence structure and function for therapeutic targeting.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were ErbB2 glycan structures determined?",{"text":117,"@type":113},"Through mass spectrometric analysis that generates a glycoform atlas of ErbB2, including N-linked and serine/threonine-linked glycosylation profiles.",{"name":119,"@type":110,"acceptedAnswer":120},"Why does the N124 glycan matter for ErbB2?",{"text":121,"@type":113},"Molecular dynamics simulations suggest the N-glycan at N124 on a long flexible loop helps stabilize ErbB2 structure, and removing N-glycosylation at N124 shortens intracellular half-life and suppresses autophosphorylation.",{"name":123,"@type":110,"acceptedAnswer":124},"How does ErbB2 glycosylation compare with EGFR?",{"text":125,"@type":113},"A structural comparison of N-glycosylated ErbB2 and EGFR shows distinct differences in the distribution and density of N-glycans across the two receptors.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},342670,1790156147,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":36,"preview_page_count":19,"preview_urls":149},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Site-speciﬁc glycosylation analysis of epidermal growth factor receptor 2 (ErbB2): exploring structure and function toward therapeutic targeting  \nNaoki Fujitani1 , * , Yasuaki Uehara1 ,2 , Shigeru Ariki1 ,3 , Ukichiro Hashimoto1 , Jo Mukai1 , Yoshihiro Hasegawa1 ,2 , Motoko Takahashi1 , *  \n1 Department of Biochemistry, Sapporo Medical University School of Medicine, S1W17, Chuo-ku, Sapporo 060-8556, Japan, 2 Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, S1W17, Chuo-ku, Sapporo 060-8556, Japan,  \n3 Department of Chemistry, Sapporo Medical University Center for Medical Education, S1W17, Chuo-ku, Sapporo 060-8556, Japan  \n*Corresponding author: Department of Biochemistry, Sapporo Medical University School of Medicine, S1W17, Chuo-ku, Sapporo 060-8556, Japan.  \nEmail: [fujitani@sapmed.ac.jp](fujitani@sapmed.ac.jp) and [takam@sapmed.ac.jp](takam@sapmed.ac.jp)  \nGlycans found on receptor tyrosine kinases (RTKs) have emerged as promising targets for cancer chemotherapy, aiming to address issues such as drug resistance. However, to effectively select the target glycans, it is crucial to deﬁne the structure and function of candidate glycans in advance. Through mass spectrometric analysis, this study presents a “glycoform atlas” of epidermal growth factor receptor 2 (ErbB2), an RTK targeted for the treatment of ErbB2-positive cancers. Our analysis provides an in-depth and sitespeciﬁc glycosylation proﬁle, including both asparagine-and serine/threonine-linked glycosylation. Molecular dynamics simulations of N-glycosylated ErbB2 incorporating the identiﬁed glycan structures suggested that the N-glycan at N124 on the long ﬂexible loop in the N-terminal region plays a role in stabilizing the ErbB2 structure. Based on the model structures obtained from the simulations, analysis employing an ErbB2 mutant deﬁcient in N-glycosylation at N124 exhibited a signiﬁcantly shorter intracellular half-life and suppressed autophosphorylation compared to wild-type ErbB2. Moreover, a structural comparison between the N-glycosylated forms of ErbB2 and its structurally homologous receptor, epidermal growth factor receptor (EGFR), demonstrated distinct variations in the distribution and density of N-glycans across these two molecules. These ﬁndings provide valuable insights into the structural and functional implications of ErbB2 glycosylation and will contribute to facilitating the establishment of glycan-targeted therapeutic strategies for ErbB2-positive cancers.  \nKey words: breast cancer; ErbB2; glycosylation; HER2; mass spectrometry.  \nIntroduction  \nThe ErbB family members, including epidermal growth factor receptor (EGFR), ErbB2 (frequently referred to as HER2), ErbB3, and ErbB4, are representative receptor tyrosine kinases (RTKs) involved in cell growth, survival, migration, and differentiation (Citri and Yarden 2006; Lemmon and Schlessinger 2010) . Aberrant gene amplification, hyperactivation, and mutation of these proteins are closely associated with tumorigenesis and cancer progression (Yarden and Sliwkowski 2001) . Consequently, various antitumor agents such as tyrosine kinase inhibitors, monoclonal antibodies, and antibody-drug conjugates, have been extensively developed and utilized in the clinical setting, particularly for targeting EGFR and ErbB2 (Gschwind et al. 2004; Hynes and Lane 2005; Yarden and Pines 2012) . However, despite the high tumor response rates with first-line treatment, cancer cells almost inevitably acquire resistance to ErbB-targeted therapies, eventually leading to therapeutic limitations (Kumagai et al. 2021) . Furthermore, aberrant ErbB signaling has been found to contribute to immune evasion, compromising the efficacy of cancer immunotherapies involving immune checkpoint inhibitors (Kumagai et al. 2021) .  \nTo overcome drug resistance and advance cancer treatment strategies, there is growing interest in exploring glycans on  \nproteins as promising therapeutic targets.","cbCaieaGHTbMj52b","https://ap.wps.com/l/cbCaieaGHTbMj52b","pdf",3757123,16,"English","# Introduction\n## ErbB receptor biology and therapeutic resistance\n## Glycans as therapeutic targets\n## Site-specific glycan analysis approaches\n# Results and implications (from main text findings)\n## Glycoform atlas from mass spectrometry\n## Molecular dynamics and the role of N124 glycan\n## Functional effects of N124 glycosylation deficiency\n## Structural comparison with EGFR and therapeutic relevance","[{\"question\":\"What is the main goal of this ErbB2 glycosylation study?\",\"answer\":\"To define the site-specific glycan structures on ErbB2 and clarify how those glycans influence structure and function for therapeutic targeting.\"},{\"question\":\"How were ErbB2 glycan structures determined?\",\"answer\":\"Through mass spectrometric analysis that generates a glycoform atlas of ErbB2, including N-linked and serine/threonine-linked glycosylation profiles.\"},{\"question\":\"Why does the N124 glycan matter for ErbB2?\",\"answer\":\"Molecular dynamics simulations suggest the N-glycan at N124 on a long flexible loop helps stabilize ErbB2 structure, and removing N-glycosylation at N124 shortens intracellular half-life and suppresses autophosphorylation.\"},{\"question\":\"How does ErbB2 glycosylation compare with EGFR?\",\"answer\":\"A structural comparison of N-glycosylated ErbB2 and EGFR shows distinct differences in the distribution and density of N-glycans across the two receptors.\"}]","Site-specific glycosylation analysis of epidermal growth factor receptor 2 (ErbB2) - exploring structure and function toward therapeutic targeting | PDF",1790047665,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53fd36643e4c22e297a625f92a6b8821.webp",983,1291,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f80615fea066ea2aa8e21bed1307820b.webp",982,1290,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d723cd10cf138f6312dfa2924943e3b8.webp",981,1289,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc154a663f3c4e616690f360d3455b6f.webp",980,1287]